Back to Results
First PageMeta Content
Ebola / Ebola virus disease / Mononegavirales / Zoonoses / Biologic / Antibody / Virus / Cambridge Antibody Technology / Symphogen / Biology / Medicine / Immune system


FOR  IMMEDIATE  RELEASE     Theraclone  Sciences’  I-­‐STAR™  Technology  Chosen  by  Wellcome  Trust     to  Identify  Therapeutic  Antibodies  Against  Ebol
Add to Reading List

Document Date: 2015-04-30 08:07:06

Open Document

File Size: 66,46 KB

Share Result on Facebook

City

SEATTLE / TCN / /

Company

Canaan Partners / Pfizer / Zenyaku Kogyo / Alexandria Real Estate Equities / Healthcare Ventures / Venture Partners / Theraclone / Versant Ventures / Amgen Ventures / Wellcome Trust / MPM Capital / BIO Ventures / Sciences Inc. / /

Currency

USD / GBP / /

Event

Funding / Business Partnership / /

Facility

ARCH Venture Partners / /

IndustryTerm

biopharmaceutical / biotechnology / antibody discovery technology / biopharmaceutical industry / /

MedicalCondition

Gastric cancer / negative breast cancer / cancer / HIV / disease / malaria / Ebola / This Ebola / small cell lung cancer / Melanoma / diseases / infectious diseases / serious influenza / infectious disease / immuno modulatory treated cancer / /

MedicalTreatment

immunotherapies / /

Position

Chief Executive Officer / Jennifer Dent President / BVGH / /

ProvinceOrState

Washington / /

Technology

STAR™ Technology / antibody discovery technology / Antibodies / biotechnology / STARTM technology / human genome / STAR technology / /

URL

www.wellcome.ac.uk / www.theraclone- / /

SocialTag